LitAlert ~~ GeneLit.com

    • Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?
    • Laot L, Sonigo C, Nobre J, Benachi A, Dervin T, El Moujahed L, Mayeur A, Stoppa-Lyonnet D, Steffann J, Grynberg M.
    • Cancers (Basel). 2022 Nov 24;14(23):5769. doi: 10.3390/cancers14235769.

    • Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
    • Viet Le B, Podszywalow-Bartnicka P, Piwocka K, Skorski T.
    • Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.

    • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
    • Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, Janjigian YY, Stadler ZK, Chang JC, Yang SR, Mandelker D, Offit K, Berger MF, Donoghue MTA, Bandlamudi C, Drilon A.
    • Nat Commun. 2022 Nov 23;13(1):7182. doi: 10.1038/s41467-022-34109-8.

    • The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.
    • Bizzarri N, D'Indinosante M, Marchetti C, Tudisco R, Turchiano F, Scambia G, Fagotti A.
    • Int J Clin Oncol. 2022 Nov 22. doi: 10.1007/s10147-022-02272-z. Epub ahead of print.

    • Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers.
    • Ogony J, Hoskin TL, Stallings-Mann M, Winham S, Brahmbhatt R, Arshad MA, Kannan N, Peña A, Allers T, Brown A, Sherman ME, Visscher DW, Knutson KL, Radisky DC, Degnim AC.
    • Breast Cancer Res Treat. 2022 Nov 16. doi: 10.1007/s10549-022-06786-y. Epub ahead of print.

    • Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    • Franzese O, Graziani G.
    • Cancers (Basel). 2022 Nov 16;14(22):5633. doi: 10.3390/cancers14225633.

    • Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
    • van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, Harmsen MG.
    • Hum Reprod Update. 2022 Nov 16:dmac038. doi: 10.1093/humupd/dmac038. Epub ahead of print.

    • Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    • Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES.
    • Prostate. 2022 Nov 16. doi: 10.1002/pros.24454. Epub ahead of print.

    • Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru.
    • Zavaleta E, Solis N, Palacios MI, Zevallos-Escobar LE, Vasquez Corales E, Bazo-Alvarez JC, Dominguez-Barrera C, Campos A, Wernhoff P, Ekstrøm PO, Møller P, Visnovska T, Hovig E, Balazar-Palacios J, Alvarez-Valenzuela K, Nakken S, Dominguez-Valentin M.
    • Cancers (Basel). 2022 Nov 15;14(22):5603. doi: 10.3390/cancers14225603.

    • The Genetics of Pancreatic Cancer
    • [No author given]
    • My Gene Counsel. Genetic Journal. 2022 Nov 14.